Viking Therapeutics' oral weight-loss pill meets expectations in mid-stage study

Viking Therapeutics' oral weight-loss pill, VK2735, demonstrated up to 12.2% body weight reduction over 13 weeks in a mid-stage study; however, the company's shares slumped 30% premarket following disclosure of a 28% drug discontinuation rate, notably higher than the 18% for placebo. This outcome is critical for the fiercely competitive $150 billion weight-loss market, where oral treatments are vying for market share against established injectable therapies from Novo Nordisk and Eli Lilly.

Analysis

Viking Therapeutics' (VKTX) mid-stage trial for its oral weight-loss pill delivered a bifurcated result, with promising efficacy overshadowed by significant tolerability concerns. The experimental drug achieved up to 12.2% body weight reduction over 13 weeks, a result that falls within the analyst expectation range of 10-15% and surpasses the 8.2% seen in an earlier trial. However, this positive data point was negated by a high discontinuation rate of 28% in the treatment arm, substantially above the 18% rate for placebo participants. The market reacted decisively to this negative signal, with VKTX shares slumping 30% in premarket trading. This high dropout rate poses a critical hurdle to the drug's future commercial viability in the projected $150 billion weight-loss market, where it faces a "tight race" against deeper-pocketed competitors Eli Lilly and Novo Nordisk, whose injectable products have already set a high bar for both efficacy and patient retention.

Key Decisions for Investors

• Investors should recognize that the market is heavily penalizing the high 28% discontinuation rate, viewing it as a potential barrier to commercial success that outweighs the solid 12.2% weight-loss efficacy.
• The setback for Viking's oral candidate may be interpreted as a positive for established market leaders Eli Lilly and Novo Nordisk, as it reinforces their competitive position by highlighting the challenges new entrants face in developing well-tolerated oral alternatives.
• It is now critical to monitor for further details from Viking explaining the root causes of the high dropout rate, as this will be the key determinant of whether the issue can be mitigated in pivotal late-stage trials.